Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Quick update: Pfizer’s tanezumab voted down!
View:
Post by endpntplay on Mar 25, 2021 3:28pm

Quick update: Pfizer’s tanezumab voted down!

"Edward Cheng, professor of reconstructive surgery at the University of Minnesota, said tanezumab “does not fill” the unmet need for an effective drug for osteoarthritis and chronic arthritis pain, explaining that it’s no better than aspirin or ibuprofen, or even placebo."

https://endpts.com/fda-adcomm-lines-up-almost-unanimously-against-pfizers-osteoarthritis-drug-tanezumab/

W
hen will pharma realize that a PH3 ready OA drug is up for grabs for the largest markets: US and Europe. Soon...?
Comment by endpntplay on Mar 25, 2021 3:32pm
More coverage and commentary: https://www.biospace.com/article/fda-advisory-committee-raises-objections-to-pfizer-and-eli-lilly-s-tanezumab/ “A drug like tanezumab that accelerates the joint destruction of the underlying osteoarthritis disease it is intended to treat but lacks any evidence of clinically meaningful benefit in comparison to use of a placebo or oral NSAIDs obviously should ...more  
Comment by TriumphSpitSix on Mar 25, 2021 11:42pm
This gives us good goal posts to aim for. Our Ph.3 needs to provide "convincing evidence of a superior efficacy" of OTEN over NSAIDs (easy) and any dose-related adverse events need to plateau (or better, trail off) by the end of the study. (Harder since we only have safety data out to 2-3 weeks tops and Ph. 3 is 12 weeks of dosing.)   This supports my prior suggestion that Antibe ...more  
Comment by MrMugsy on Mar 26, 2021 10:05am
Triumph ... superiority in safety (that's the key). On the efficacy side (pain and inflammation) - we are not aiming for superiority - want to be "as good" as the other alternatives, with less NSAID (active ingredient). I think we mean the same - just wanted to clarify.
Comment by TriumphSpitSix on Mar 26, 2021 11:47am
This sentence in the article is clearly mistyped: "The panel overwhelmingly said the risks of taking the medication do not outweigh the therapeutic benefits." That obviously should say (take your pick): "The panel overwhelmingly said the risks of taking the medication outweigh the therapeutic benefits." OR The panel overwhelmingly said the therapeutic benefits of taking ...more  
Comment by Marky1 on Mar 25, 2021 3:37pm
Well said End..TU...one day they'll open their eyes and wallets and come charging...Widsh Stern would be doing more on our behalf 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities